ZyVersa Therapeutics, Inc. (ZVSA)
Chart Events
Performance Outlook
| Previous Close | 2.2400 |
| Open | 2.1800 |
| Bid | 2.0100 x 800 |
| Ask | 2.1000 x 1100 |
| Day's Range | 1.9600 - 2.1900 |
| 52 Week Range | 1.3800 - 25.0000 |
| Volume | |
| Avg. Volume | 353,291 |
| Market Cap | 17.891M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
ZyVersa Therapeutics Reports Inducement Grant to Newly Appointed Chief Medical Officer Under Nasdaq Listing Rule 5635(c)(4)
WESTON, Fla., Jan. 27, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for treatment of renal and inflammatory diseases with high unmet medical needs, today announced the grant of an inducement equity award outside ZyVersa’s 2022 Equity Incentive Plan to its newly appointed Chief Medical Officer and Senior Vice President of Medical Affairs, Dr. Pablo Guzman. The grants were appr
- GlobeNewswire
ZyVersa Therapeutics to Present at BIO CEO & Investor Conference
CEO Stephen C. Glover to provide key updates on the development status of ZyVersa’s Phase 2a-ready cholesterol efflux mediator VAR 200 for renal disease and inflammasome ASC inhibitor, IC 100 WESTON, Fla., Jan. 25, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of inflammatory and renal diseases with high unmet medical needs, announced today that Stephen C. Gl
- GlobeNewswire
ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Present at the Virtual Investor 2023 Companies to Watch Event
Stephen C. Glover Stephen C. Glover, Co-founder, Chairman, CEO, President, ZyVersa Therapeutics Live video webcast on Wednesday, January 18th at 2:00 PM ET Mr. Glover will highlight the development status of ZyVersa’s phase 2a-ready VAR 200 for renal disease and inflammasome ASC inhibitor, IC 100 WESTON, Fla., Jan. 11, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or "ZyVersa"), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for treatmen
